| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Gahr, K Rehbaum, B J Conneman. Clozapine-associated development of second-onset obsessive compulsive symptoms in schizophrenia: impact of clozapine serum levels and fluvoxamine add-on. Pharmacopsychiatry. vol 47. issue 3. 2015-01-07. PMID:24846087. |
among antiserotonergic second generation antipsychotics (sga), particularly treatment with clozapine (clz) is associated with the development of second-onset obsessive compulsive symptoms (ocs) in schizophrenia. |
2015-01-07 |
2023-08-13 |
Not clear |
| Amresh Shrivastava, Megan Johnston, Nilesh Shah, Larry Stitt, Shivanshu Shrivastava, Avinash De Sous. Clozapine response and pre-treatment EEG-is there some kind of relationship. Industrial psychiatry journal. vol 23. issue 1. 2014-12-23. PMID:25535440. |
clozapine has been used widely in the management of treatment-resistant schizophrenia. |
2014-12-23 |
2023-08-13 |
Not clear |
| Kara E O'Connell, Jogin Thakore, Kumlesh K De. Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine. Schizophrenia research. vol 156. issue 1. 2014-12-22. PMID:24742875. |
pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine. |
2014-12-22 |
2023-08-13 |
Not clear |
| Raquelle I Mesholam-Gately, Lauren E Gibson, Larry J Seidman, Alan I Gree. Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine. Schizophrenia research. vol 155. issue 1-3. 2014-12-17. PMID:24685823. |
schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine. |
2014-12-17 |
2023-08-12 |
Not clear |
| Maria Rosaria A Muscatello, Antonio Bruno, Pasquale De Fazio, Cristina Segura-Garcia, Gianluca Pandolfo, Rocco Zoccal. Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. Expert opinion on pharmacotherapy. vol 15. issue 16. 2014-12-15. PMID:25284216. |
augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. |
2014-12-15 |
2023-08-13 |
Not clear |
| Maria Rosaria A Muscatello, Antonio Bruno, Pasquale De Fazio, Cristina Segura-Garcia, Gianluca Pandolfo, Rocco Zoccal. Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. Expert opinion on pharmacotherapy. vol 15. issue 16. 2014-12-15. PMID:25284216. |
although clozapine (clz) is considered the best evidence-based therapeutic option for treatment of resistant schizophrenia patients, a significant proportion of clz-treated patients show a partial or inadequate response to treatment, leading to increased healthcare cost and poor quality of life for affected individuals. |
2014-12-15 |
2023-08-13 |
Not clear |
| Thomas Schnell, Dagmar Koethe, Anna Krasnianski, Stefanie Gairing, Knut Schnell, Jörg Daumann, Euphrosyne Gouzoulis-Mayfran. Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. The American journal on addictions. vol 23. issue 3. 2014-12-10. PMID:24628830. |
ziprasidone versus clozapine in the treatment of dually diagnosed (dd) patients with schizophrenia and cannabis use disorders: a randomized study. |
2014-12-10 |
2023-08-12 |
Not clear |
| Danielle Gulick, David T Chau, Jibran Y Khokhar, Ree Dawson, Alan I Gree. Desipramine enhances the ability of risperidone to decrease alcohol intake in the Syrian golden hamster. Psychiatry research. vol 218. issue 3. 2014-12-10. PMID:24836200. |
the atypical antipsychotic clozapine reduces alcohol drinking in patients with schizophrenia. |
2014-12-10 |
2023-08-13 |
Not clear |
| Jari-Pekka Klemettilä, Olli Kampman, Niko Seppälä, Merja Viikki, Mari Hämäläinen, Eeva Moilanen, Esa Leinone. Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. Psychiatry research. vol 218. issue 3. 2014-12-10. PMID:24837425. |
cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. |
2014-12-10 |
2023-08-13 |
Not clear |
| Jari-Pekka Klemettilä, Olli Kampman, Niko Seppälä, Merja Viikki, Mari Hämäläinen, Eeva Moilanen, Esa Leinone. Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. Psychiatry research. vol 218. issue 3. 2014-12-10. PMID:24837425. |
metabolic syndrome is associated with both schizophrenia and antipsychotic medication, especially clozapine, with alterations in inflammatory cytokines and adipokines. |
2014-12-10 |
2023-08-13 |
Not clear |
| Jari-Pekka Klemettilä, Olli Kampman, Niko Seppälä, Merja Viikki, Mari Hämäläinen, Eeva Moilanen, Esa Leinone. Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. Psychiatry research. vol 218. issue 3. 2014-12-10. PMID:24837425. |
in this study we assessed the serum levels of cytokines/adipokines il-6, il-1ra, hs-crp and adiponectin, and components of metabolic syndrome in 190 patients with treatment resistant schizophrenia treated with clozapine. |
2014-12-10 |
2023-08-13 |
Not clear |
| Jari-Pekka Klemettilä, Olli Kampman, Niko Seppälä, Merja Viikki, Mari Hämäläinen, Eeva Moilanen, Esa Leinone. Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. Psychiatry research. vol 218. issue 3. 2014-12-10. PMID:24837425. |
we conclude that there are partly gender dependent cytokine and adipokine alterations in patients with schizophrenia on clozapine treatment associated with metabolic comorbidity. |
2014-12-10 |
2023-08-13 |
Not clear |
| Nazife Gamze Usta, Cana Aksoy Poyraz, Melih Aktan, Alaattin Dura. Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma. Therapeutic advances in psychopharmacology. vol 4. issue 6. 2014-12-09. PMID:25489479. |
clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma. |
2014-12-09 |
2023-08-13 |
Not clear |
| Nazife Gamze Usta, Cana Aksoy Poyraz, Melih Aktan, Alaattin Dura. Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemma. Therapeutic advances in psychopharmacology. vol 4. issue 6. 2014-12-09. PMID:25489479. |
clozapine remains the antipsychotic of choice for refractory schizophrenia. |
2014-12-09 |
2023-08-13 |
Not clear |
| Johann Steiner, Daniel Martins-de-Souza, Kolja Schiltz, Zoltan Sarnyai, Sabine Westphal, Berend Isermann, Henrik Dobrowolny, Christoph W Turck, Bernhard Bogerts, Hans-Gert Bernstein, Tamas L Horvath, Lorenz Schild, Gerburg Keilhof. Clozapine promotes glycolysis and myelin lipid synthesis in cultured oligodendrocytes. Frontiers in cellular neuroscience. vol 8. 2014-12-05. PMID:25477781. |
our findings support the superior impact of clozapine on white matter integrity in schizophrenia as previously observed, suggesting that this drug improves the energy supply and myelin lipid synthesis in oligodendrocytes. |
2014-12-05 |
2023-08-13 |
Not clear |
| Cicek Hocaogl. Clozapine-induced rabbit syndrome: a case report. Mental illness. vol 1. issue 1. 2014-12-05. PMID:25478081. |
we present the case history of a 44-year old female patient treated for paranoid schizophrenia for 22 years and rs during her last 10-month clozapine treatment. |
2014-12-05 |
2023-08-13 |
rabbit |
| Eila Repo-Tiihonen, Tero Hallikainen, Päivi Kivistö, Jari Tiihone. Antipsychotic Polypharmacy in Clozapine Resistant Schizophrenia: A Randomized Controlled Trial of Tapering Antipsychotic Co-treatment. Mental illness. vol 4. issue 1. 2014-12-05. PMID:25478102. |
antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment. |
2014-12-05 |
2023-08-13 |
human |
| Eila Repo-Tiihonen, Tero Hallikainen, Päivi Kivistö, Jari Tiihone. Antipsychotic Polypharmacy in Clozapine Resistant Schizophrenia: A Randomized Controlled Trial of Tapering Antipsychotic Co-treatment. Mental illness. vol 4. issue 1. 2014-12-05. PMID:25478102. |
there is a considerable disparity between clinical practice and recommendations based on meta-analyses of antipsychotic polypharmacy in clozapine resistant schizophrenia. |
2014-12-05 |
2023-08-13 |
human |
| H Y Meltzer, J-P Lindenmayer, J Kwentus, D B Share, R Johnson, K Jayathilak. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. Schizophrenia research. vol 154. issue 1-3. 2014-11-26. PMID:24630262. |
it has been suggested that atypical antipsychotic drugs (a-apds) other than clozapine may be effective to improve positive symptoms in some patients with treatment resistant schizophrenia (trs), if both the dose is higher, and the duration of the trial longer, than those which have been ineffective in non-trs (ntrs) patients. |
2014-11-26 |
2023-08-12 |
Not clear |
| Marta Bosia, Andrea Zanoletti, Marco Spangaro, Mariachiara Buonocore, Margherita Bechi, Federica Cocchi, Adele Pirovano, Cristina Lorenzi, Placido Bramanti, Enrico Smeraldi, Roberto Cavallar. Factors affecting cognitive remediation response in schizophrenia: the role of COMT gene and antipsychotic treatment. Psychiatry research. vol 217. issue 1-2. 2014-11-26. PMID:24656901. |
in the present study, we analyzed the interaction between pharmacological treatment (clozapine vs typical/atypical d2 blockers) and comt rs4680 polymorphism on cognitive changes after cognitive remediation therapy, in a sample of 98 clinically stabilized patients with schizophrenia. |
2014-11-26 |
2023-08-12 |
Not clear |